The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

June 7, 2013 updated by: AstraZeneca

A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.

The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.

Study Overview

Status

Completed

Conditions

Detailed Description

MC MD

Study Type

Observational

Enrollment (Actual)

1514

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
      • Agartala, India
        • Research Site
      • Agra, India
        • Research Site
      • Ahmedabad, India
        • Research Site
      • Aligarh, India
        • Research Site
      • Ambattur, India
        • Research Site
      • Amritsar, India
        • Research Site
      • Aurangabad, India
        • Research Site
      • Bangalore, India
        • Research Site
      • Barelly, India
        • Research Site
      • Baroda, India
        • Research Site
      • Batanagar, India
        • Research Site
      • Beed, India
        • Research Site
      • Belgaum, India
        • Research Site
      • Bhagal, India
        • Research Site
      • Bhongi, India
        • Research Site
      • Bhopal, India
        • Research Site
      • Bhuj, India
        • Research Site
      • Burdwan, India
        • Research Site
      • Chandigarh, India
        • Research Site
      • Chennai, India
        • Research Site
      • Chomv, India
        • Research Site
      • Coimbatore, India
        • Research Site
      • Davangere, India
        • Research Site
      • Delhi, India
        • Research Site
      • Dhule, India
        • Research Site
      • Dombivli, India
        • Research Site
      • Ellisbridge, India
        • Research Site
      • Fariadad, India
        • Research Site
      • Faridabad, India
        • Research Site
      • Gandhinagar, India
        • Research Site
      • Ghatkopar East, India
        • Research Site
      • Ghaziabad, India
        • Research Site
      • Gulbarga, India
        • Research Site
      • Guntur, India
        • Research Site
      • Gurgaon, India
        • Research Site
      • Gwalior, India
        • Research Site
      • Hanamkonda, India
        • Research Site
      • Hooghly, India
        • Research Site
      • Hubli, India
        • Research Site
      • Hyd, India
        • Research Site
      • Hyderabad, India
        • Research Site
      • Indore, India
        • Research Site
      • Jabalpur, India
        • Research Site
      • Jaipur, India
        • Research Site
      • Jalandhar, India
        • Research Site
      • Jalgoon, India
        • Research Site
      • Kakinada, India
        • Research Site
      • Kanpur, India
        • Research Site
      • Karad, India
        • Research Site
      • Karimnagar, India
        • Research Site
      • Kolhapur, India
        • Research Site
      • Kolkata, India
        • Research Site
      • Kolkata-, India
        • Research Site
      • Kulhapu, India
        • Research Site
      • Kumta, India
        • Research Site
      • Lucknow, India
        • Research Site
      • Ludhiana, India
        • Research Site
      • Madhyamgram, India
        • Research Site
      • Madurai, India
        • Research Site
      • Miroj, India
        • Research Site
      • Mohali, India
        • Research Site
      • Mozda, India
        • Research Site
      • Mrit Home, India
        • Research Site
      • Mulund, India
        • Research Site
      • Mumbai, India
        • Research Site
      • Murshidabad, India
        • Research Site
      • Nadiad, India
        • Research Site
      • Nagpur, India
        • Research Site
      • Nasik, India
        • Research Site
      • Naugloi, India
        • Research Site
      • Navi Mumbai, India
        • Research Site
      • Nesul, India
        • Research Site
      • New Delhi, India
        • Research Site
      • New Panvel, India
        • Research Site
      • Newdelhi, India
        • Research Site
      • Nipani, India
        • Research Site
      • Op Inchapur, India
        • Research Site
      • Palanpur, India
        • Research Site
      • Panvel., India
        • Research Site
      • Parganas (Wb), India
        • Research Site
      • Pune, India
        • Research Site
      • Raipur, India
        • Research Site
      • Rajkot, India
        • Research Site
      • Sahibabad,Gzb, India
        • Research Site
      • Secenderabad, India
        • Research Site
      • Shakar Pur, India
        • Research Site
      • Shimoga, India
        • Research Site
      • Sonarpur, India
        • Research Site
      • Sowcarpet, India
        • Research Site
      • Surat, India
        • Research Site
      • Thane, India
        • Research Site
      • Tirupati, India
        • Research Site
      • Ulhasnagar, India
        • Research Site
      • Vadodara, India
        • Research Site
      • Vijayawada, India
        • Research Site
      • Virar, India
        • Research Site
      • Visakhapatnam, India
        • Research Site
      • Vizag, India
        • Research Site
      • Warangal, India
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Primary hypertensive patients

Description

Inclusion Criteria:

  • Newly diagnosed essential hypertension patients will be eligible for the study.
  • Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg

Exclusion Criteria:

  • History of coronary artery disease
  • History of diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of SO in newly diagnosed hypertensive patients
Time Frame: Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion.
Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion.

Secondary Outcome Measures

Outcome Measure
Time Frame
Association of SO and heart rate.
Time Frame: Visits 1-3
Visits 1-3
Subjective symptoms noticed by the doctor.
Time Frame: 1st visit
1st visit
To record the drugs used in the treatment of patients diagnosed with hypertension.
Time Frame: Visits 1-3
Visits 1-3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Dr T.N.C. Padmanabhan, Dr. Padmanabhan Heart Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Actual)

February 1, 2012

Study Completion (Actual)

February 1, 2012

Study Registration Dates

First Submitted

February 3, 2011

First Submitted That Met QC Criteria

February 10, 2011

First Posted (Estimate)

February 14, 2011

Study Record Updates

Last Update Posted (Estimate)

June 10, 2013

Last Update Submitted That Met QC Criteria

June 7, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-CIN-DUM-2010/2

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Essential Hypertension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe